CDC NEWS


powered by Surfing Waves


Latest News


Phase 3 trial of Novavax investigational COVID-19 vaccine opens


28 Dec 2020

The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor.


Older Adults’ Perspectives on a COVID-19 Vaccine


23 Dec 2020

As of December 4, 2020, cases of novel coronavirus disease 2019 (COVID-19) have topped 14.3 million in the US with nearly 300 000 associated deaths. While mitigation measures such as social distancing, use of face coverings, and avoidance of crowds can help keep case counts in check, a safe and effective COVID-19 vaccine will be essential to ending the pandemic.


Coronavirus Vaccines


02 Oct 2020

Leading COVID-19 vaccine candidates rely on new genetic technologies that have fast-tracked development and testing. This video explains the principles underlying the leading DNA, messenger RNA (mRNA), and viral vector vaccine candidates, and how they might induce immunity to SARS-CoV-2 infection.




Articles


Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3


10 May 2022

Older patients in Israel who received a fourth dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine were more than 3 times less likely to develop severe COVID-19 than those who received only 3 doses. But while protection against severe disease did not wane during the testing period, protection against confirmed infection appeared short-lived.




Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19


20 Apr 2022

Risk of SARS-CoV-2 reinfection among unvaccinated people with prior COVID-19 is a subject of debate.1,2 We performed a survival analysis in a large US population to assess the degree and duration of protection associated with natural immunity in unvaccinated individuals.




Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster


12 Apr 2022

The risk of adolescents developing myocarditis is lower after a booster dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine than after the second dose, according to a CDC analysis of data from the Vaccine Adverse Event Reporting System (VAERS). Myocarditis is a rare but serious adverse event associated with COVID-19 mRNA vaccination. To assess whether this adverse event was also associated with booster doses administered to adolescents, the authors analyzed reports submitted to the VAERS system and v-safe between December 9, 2021, and February 20, 2022.




Even Mild COVID-19 May Change the Brain


23 Mar 2022

Alarge study comparing brain scans from the same individuals before and after SARS-CoV-2 infection suggests that brain changes could be a lingering outcome of even mild COVID-19. Writing in Nature, researchers at Oxford University’s Wellcome Centre for Integrative Neuroimaging reported that several months after study participants had SARS-CoV-2 infections, they had more gray matter loss and tissue abnormalities, mainly in the areas of the brain associated with smell, and more brain size shrinkage than participants who hadn’t been infected with the virus.




Risks and burdens of incident diabetes in long COVID: a cohort study


21 Mar 2022

Background There is growing evidence suggesting that beyond the acute phase of SARS-CoV-2 infection, people with COVID-19 could experience a wide range of post-acute sequelae, including diabetes. However, the risks and burdens of diabetes in the post-acute phase of the disease have not yet been comprehensively characterised. To address this knowledge gap, we aimed to examine the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection. Interpretation In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era. Post-acute COVID-19 care should involve identification and management of diabetes.




Enroll for Free